Allocate mean age related utility weight for adult population to additional survival in this patient group

This is based on i) the mean age of diagnosis for renal cell using the ICD codes CD64:66, 68 as in the assessment report and ONS data for cancer registrations 2004 and ii) weights from the York MVH study (Kind, Hardman and Macran (1999) CHE Discussion paper 172)

mean age (yrs) at diagnosis:

66 males 67 females

utility in this age group

0.78

Sunitinib vs IFN, using Committee's preferred assumptions (and no restriction on time of administration of IFN):	amily in the age givenp	00					Dalativa	- la 4 a		
Sunitinib vs IFN, using all final ITT data in Assessment Group model: 20868 0.22 0.2 104340 0.1716 121608 5.22 3.48 6.08 4. Sunitinib vs IFN, using Committee's preferred assumptions (and no restriction on time of administration of IFN):								gnts		
20868 0.22 0.2 104340 0.1716 121608 5.22 3.48 6.08 4. Sunitinib vs IFN, using Committee's preferred assumptions (and no restriction on time of administration of IFN):	Scenario IC	<i>I LYG</i>	IQ (original)	ICER (origin	IQ (max)	ICER (max	Original Q	1	max Q	
Sunitinib vs IFN, using Committee's preferred assumptions (and no restriction on time of administration of IFN):	Sunitinib vs IFN, using all fina	al ITT data in As	sessment Group	model:			,	•		•
	2086	8 0.22	0.2	104340	0.1716	121608	5.22	3.48	6.08	4.05
31921 0.86 0.59 54103 0.6708 47586 2.71 1.80 2.38 1.	Sunitinib vs IFN, using Comm	nittee's preferred	d assumptions (ar	nd no restriction	on time of adminis	stration of IF	N):	•		
	3192	1 0.86	0.59	54103	0.6708	47586	2.71	1.80	2.38	1.59
Temsirolimus vs IFN, using manufacturer's model with Assessment Group IFN administration costs	Temsirolimus vs IFN, using n	nanufacturer's m	nodel with Assess	ment Group IFN	administration co	sts				
13717 0.221 0.134 102366 0.17238 <mark> 79574</mark> 5.12 3.41 3.98 2.	1371	7 0.221	0.134	102366	0.17238	79574	5.12	3.41	3.98	2.65
Sorafenib vs BSC, using 'failed IFN' subgroup with patient access scheme and new price	Sorafenib vs BSC, using 'faile	ed IFN' subgroup	p with patient acce	ess scheme and	new price		_			
20153 0.425643 0.31 65929 0.33200154 60702 3.25 2.17 3.04 2.	2015	3 0.425643	0.31	65929	0.33200154	60702	3.25	2.17	3.04	2.02